Company Mission
PrognosDx is aimed at providing genuine hope to cancer patients through its breakthrough epigenetic tests which identify a unique molecular signature in each patient’s tumor empowering physicians with the ability to select the most effective course of therapy.
About Us
PrognosDx Health, Inc. is a biotechnology company aiming to significantly improve the treatment of cancer and other complex diseases through powerful epigenetic technology. PrognosDx’s tissue-based global cellular histone biomarkers have been confirmed independently by researchers around the globe to be prognostic for multiple cancers and demonstrated by our scientific founders in a study published in the JCO to have direct relevance to therapeutic response prediction for 5-Fluorouracil.. The technology is also poised to be a powerful tool for drug pipeline prioritization and development of novel class of drugs targeting aggressive cancer cells. A network of renowned academic researchers and clinicians with expertise in the fields of cancer and epigenetics supports PrognosDx and its personalized healthcare laboratory tests and services.
PrognosDx is currently aimed at providing CLIA-based laboratory developed tests enabling treating oncologists and urologists access clinically relevant independent Epigenetic information through identifying patients with low or high risk of recurrence of cancer so that the most appropriate course of treatment can be selected at the right time for the right patient.
